KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $48.3 million.

  • Xenon Pharmaceuticals' Total Liabilities rose 2685.72% to $48.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year increase of 2685.72%. This contributed to the annual value of $43.2 million for FY2024, which is 1724.38% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Total Liabilities is $48.3 million, which was up 2685.72% from $40.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Total Liabilities' 5-year high stood at $48.3 million during Q3 2025, with a 5-year trough of $14.4 million in Q1 2021.
  • In the last 5 years, Xenon Pharmaceuticals' Total Liabilities had a median value of $32.9 million in 2023 and averaged $30.8 million.
  • In the last 5 years, Xenon Pharmaceuticals' Total Liabilities tumbled by 7066.34% in 2021 and then soared by 10315.93% in 2023.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Total Liabilities stood at $22.0 million in 2021, then soared by 48.58% to $32.6 million in 2022, then rose by 12.95% to $36.9 million in 2023, then grew by 17.24% to $43.2 million in 2024, then increased by 11.77% to $48.3 million in 2025.
  • Its Total Liabilities stands at $48.3 million for Q3 2025, versus $40.3 million for Q2 2025 and $39.3 million for Q1 2025.